For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP158

3499N

Dr.Sanjana Vinod
Membership No Author Name Email Mobile
3499N Dr.Sanjana Vinod sanjanachoondal@gmail.com 9915507520
Uvea

Real-World Experience with JAK Inhibitors Across the Spectrum of Non-infectious Ocular Inflammation

Purpose:To evaluate the efficacy,steroid-sparing effect,multimodal imaging outcomes,tear cytokine profile& safety of JAKinhibitors in refractory noninfectious ocular inflammatory diseases
Methods:Retrospective observational study of 75 patients treated with tofacitinib, baricitinib or upadacitinib.Clinical features, imaging, treatment response, steroid use, safety and tear cytokines were analysed
Results:Mean age-40.2±18.6yrs; panuveitis was most common-41.3%. Tofacitinib was used in 92%, with patients receiving a median of 2 prior DMARDs. Overall response was 89.3%.OCT&FFA confirmed reduced inflammatory activity with significant steroid sparing.Tear IL-17A & MMP-9 were elevated in active and clinically quiet fellow eyes, suggesting subclinical bilateral inflammation
Conclusion: JAKi are effective steroid-sparing agents for refractory ocular inflammation. Imaging confirmed sustained disease control, while tear IL-17A and MMP-9 may serve as non-invasive biomarkers of subclinical disease

Membership No Author Name Email Mobile
717 Dr.Padmamalini Mahendradas m.padmamalini@gmail.com 9845551862
1662N Dr.Ankush Ashok Kawali akawali332@gmail.com 9632368641
2965 Dr.Sai Bhakti Mishra drsaibhakti@gmail.com 8105490765